- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 5: Proper Use of Tests
Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.
Although diagnostic testing is not currently regulated by the FDA, payers will commonly take a look at what’s going on in other areas where there is FDA approval and determine what sorts of signals can come from claims data and other information, said Bryan Loy, MD, MBA.
“Having some processes in place to not only measure signals, but also how folks are using the test and the results has become very important,” he said.
Daniel Hayes, MD, added that he hopes CancerLinQ from the American Society of Clinical Oncology will ensure that physicians are using tests properly, which is a matter of education and training.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
